CPH:SMSMED Income Statement

Financials in millions DKK. Fiscal year is October - September.

Millions DKK. Fiscal year is Oct - Sep.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	Sep '20 Sep 30, 2020
Revenue	226.68	191.19	110.53	71.64	41.95
Revenue Growth (YoY)	18.56%	72.98%	54.29%	70.78%	-
Cost of Revenue	186.56	156.46	87.85	57.76	34.59
Gross Profit	40.12	34.73	22.68	13.88	7.36
Selling, General & Admin	19.11	13.65	7.33	2.98	1.37
Operating Expenses	26.37	18.1	7.94	3.01	1.39
Operating Income	13.75	16.63	14.74	10.87	5.96
Interest Expense	-5.23	-0.98	-0.25	-0.54	-0.28
Interest & Investment Income	1.55	0.14	0.22	-	-
Currency Exchange Gain (Loss)	-	-	-	0.2	0.13
Pretax Income	10.07	15.79	14.71	10.54	5.82
Income Tax Expense	2.28	3.57	3.34	2.38	1.31
Net Income	7.79	12.22	11.37	8.16	4.51
Net Income to Common	7.79	12.22	11.37	8.16	4.51
Net Income Growth	-36.30%	7.49%	39.42%	80.82%	-
Shares Outstanding (Basic)	27	27	27	-	-
Shares Outstanding (Diluted)	27	27	27	-	-
Shares Change (YoY)	0.57%	2.22%	-	-	-
EPS (Basic)	0.28	0.45	0.43	-	-
EPS (Diluted)	0.28	0.45	0.43	-	-
EPS Growth	-36.66%	5.15%	-	-	-
Free Cash Flow	-15.08	-49.19	-24.33	4.02	9.38
Free Cash Flow Per Share	-0.55	-1.80	-0.91	-	-
Gross Margin	17.70%	18.16%	20.52%	19.38%	17.54%
Operating Margin	6.07%	8.70%	13.34%	15.18%	14.22%
Profit Margin	3.44%	6.39%	10.29%	11.39%	10.75%
Free Cash Flow Margin	-6.65%	-25.73%	-22.01%	5.62%	22.36%
EBITDA	21.01	21.08	15.35	10.9	5.99
EBITDA Margin	9.27%	11.03%	13.89%	15.21%	14.28%
D&A For EBITDA	7.26	4.46	0.61	0.02	0.02
EBIT	13.75	16.63	14.74	10.87	5.96
EBIT Margin	6.07%	8.70%	13.34%	15.18%	14.22%
Effective Tax Rate	22.66%	22.60%	22.70%	22.61%	22.46%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.